Zanubrutinib

Status:
Red
Decision Date:
July 2022
 

Comments

RED:

  • NICE TA833 - Zanubrutinib for treating Waldenstrom’s macroglobulinaemia. NHSE commissioned. (Decision date - November 2022)
  • SSC2569 - Zanubrutinib for treating chronic lymphocytic leukaemia. NHSE commissioned. (Decision date: November 2023)
  • NICE TA931 Zanubrutinib for treating chronic lymphocytic leukaemia. NHSE commissioned (Decision date - December 2023)


Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app